Last reviewed · How we verify
Epigallocatechin-3-Gallate
At a glance
| Generic name | Epigallocatechin-3-Gallate |
|---|---|
| Sponsor | Han Xi Zhao |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Epigallocatechin Gallate (EGCG) as a Flushing Agent During Full Pulpotomy in Mature Permanent Molars With Irreversible Pulpitis (NA)
- FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea (PHASE3)
- Reducing Frailty for Older Cancer Survivors Using Supplements II (PHASE2)
- Supplementation With Sirtuin Activators in Women With Increased Body Weight (NA)
- Vitamin D, Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in Uterine Fibroid (NA)
- Clinical Trial of Green Tea Catechins in Men on Active Surveillance (PHASE2)
- Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients (PHASE1)
- Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epigallocatechin-3-Gallate CI brief — competitive landscape report
- Epigallocatechin-3-Gallate updates RSS · CI watch RSS
- Han Xi Zhao portfolio CI